NAD Warns Firms Bioavailability Claims Must Fit The Evidence
This article was originally published in The Tan Sheet
Executive Summary
Supplement firms making bioavailability claims, and addressing how or where an ingredient is absorbed, is metabolized and reaches targeted cells, often stretch inconclusive science to imply that the nutrients ingested are completely released during the digestive process, a National Advertising Division attorney says.
You may also be interested in...
People In Brief
Herbalife brings on Dentali as botanical sciences VP; NACDS expands Nicholson’s role; Innophos announces interim CFO; George Hamilton new face of Infusion Life Sciences; Aker BioMarine names sales VP; Atteryd to chair Food Supplements Europe.
FDA Details “Quality Agreements” For Marketers, Contract Manufacturers
The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.
FDA Details “Quality Agreements” For Marketers, Contract Manufacturers
The “Contract Manufacturing Arrangements for Drugs: Quality Agreements” draft guidance describes how parties involved in contract manufacturing of drugs can employ quality agreements to delineate their responsibilities and ensure drug quality, safety and efficacy.